



HEXTAR HEALTHCARE BERHAD (199601000297) (372642-U)

Condensed Consolidated Statements of Comprehensive Income for the third quarter ended 30 September 2025

These figures have not been audited

	Individual Period		Cumulative Period	
	2025 Current Year Quarter ended 30 September RM'000	2024 Preceding Year Quarter ended 30 September RM'000	2025 Current Year to-Date ended 30 September RM'000	2024 Preceding Year to-Date ended 30 September RM'000
Revenue	35,743	30,434	112,578	105,296
Cost of sales	(36,700)	(30,794)	(116,588)	(102,063)
Gross Profit/(Loss)	(957)	(360)	(4,010)	3,233
Other gains and losses	(213)	(842)	16	770
Operating expenses	(3,183)	(3,514)	(9,974)	(11,017)
Loss from operations	(4,353)	(4,716)	(13,968)	(7,014)
Finance costs	(65)	(47)	(270)	(149)
Share of losses in an associate	(978)	(407)	(2,030)	(1,184)
Loss before tax	(5,396)	(5,170)	(16,268)	(8,347)
Income tax (expense)/credit	(413)	1,110	2,699	2,418
LOSS FOR THE PERIOD ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY	(5,809)	(4,060)	(13,569)	(5,929)
Other comprehensive income, net of tax:				
Foreign currency translation differences for foreign operations	33	(1,951)	1,244	(2,067)
Total comprehensive loss for the period attributable to Equity holders of the Company	(5,776)	(6,011)	(12,325)	(7,996)
Loss per share:				
Basic (sen)	(0.53)	(0.40)	(1.23)	(0.58)
Weighted average number of shares	1,102,110,781	1,025,629,892	1,102,110,781	1,025,629,892

The condensed consolidated statements of comprehensive income should be read in conjunction with the audited financial statements for the year ended 31 December 2024 and the accompanying notes attached to the interim financial statements.



HEXTAR HEALTHCARE BERHAD (199601000297) (372642-U)

Condensed Consolidated Statements of Financial Position as of 30 September 2025

These figures have not been audited

	As at 30 September 2025 RM'000	As at 31 December 2024 RM'000
ASSETS		
Non-current Assets		
Property, plant and equipment	170,201	174,167
Prepaid lease payments	4,458	16,336
Deferred tax asset	17,065	12,855
Other investments	176,596	178,626
Right-of-use assets	4,428	2,819
	<u>372,748</u>	<u>384,803</u>
Current Assets		
Inventories	56,059	63,862
Trade receivables	14,522	19,077
Other receivables	57,516	62,166
Cash and bank balances	10,123	9,217
	<u>138,220</u>	<u>154,322</u>
TOTAL ASSETS	<u>510,968</u>	<u>539,125</u>
EQUITY AND LIABILITIES		
Equity attributable to equity holders of the Company		
Issued capital	361,387	361,387
Treasury shares	(48,191)	(48,191)
Other reserves	(48,200)	(38,116)
Retained earnings	219,421	232,990
TOTAL EQUITY	<u>484,417</u>	<u>508,070</u>
Non-current Liabilities		
Borrowings	51	115
Lease liabilities	3,277	1,688
Deferred tax liabilities	2,349	1,933
	<u>5,677</u>	<u>3,736</u>
Current Liabilities		
Trade payables	9,023	10,300
Other payables	8,780	15,095
Lease liabilities	1,268	1,252
Borrowings	1,803	672
	<u>20,874</u>	<u>27,319</u>
TOTAL LIABILITIES	<u>26,551</u>	<u>31,055</u>
TOTAL EQUITY AND LIABILITIES	<u>510,968</u>	<u>539,125</u>
Net asset per share (RM)	0.44	0.46

The condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the year ended 31 December 2024 and the accompanying notes attached to the interim financial statements.



HEXTAR HEALTHCARE BERHAD (199601000297) (372642-U)

Condensed Consolidated Statements of Changes in Equity for the third quarter ended 30 September 2025

These figures have not been audited

	Attributable to Equity Holders of the Company						Total Equity RM'000
	Share Capital RM'000	Treasury Shares RM'000	Revaluation Reserves RM'000	Fair Value Reserves RM'000	Translation Reserves RM'000	Retained Earnings RM'000	
As at 01 January 2024	341,308	(48,191)	413	-	1,989	246,910	542,429
Total comprehensive loss for the period	-	-	-	-	-	(5,929)	(5,929)
Issuance of new shares	20,079	-	-	-	-	-	20,079
Effects of foreign exchange differences	-	-	-	-	(2,067)	-	(2,067)
As at 30 September 2024	<u>361,387</u>	<u>(48,191)</u>	<u>413</u>	<u>-</u>	<u>(78)</u>	<u>240,981</u>	<u>554,512</u>
As at 01 January 2025	361,387	(48,191)	413	(38,648)	119	232,990	508,070
Total comprehensive loss for the period	-	-	-	-	-	(13,569)	(13,569)
Changes in fair value of other assets	-	-	-	(11,328)	-	-	(11,328)
Effects of foreign exchange differences	-	-	-	-	1,244	-	1,244
As at 30 September 2025	<u>361,387</u>	<u>(48,191)</u>	<u>413</u>	<u>(49,976)</u>	<u>1,363</u>	<u>219,421</u>	<u>484,417</u>

The condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 December 2024 and the accompanying notes attached to the interim financial statements.



HEXTAR HEALTHCARE BERHAD (199601000297) (372642-U)

Condensed Consolidated Statements of Cashflows for the third quarter ended 30 September 2025

These figures have not been audited

	2025 Year-to-Date ended 30 September RM'000	2024 Year ended 31 December RM'000
Loss before tax	(16,268)	(18,981)
Adjustments for non-cash flow items	13,981	37,895
Operating profit/(loss) before changes in working capital	(2,287)	18,914
(Increase)/Decrease in current assets:		
Inventories	7,992	(33,129)
Trade and other receivables	4,049	(4,260)
Increase/(Decrease) in current liabilities:		
Trade and other payables	(7,462)	4,101
Cash from/(used in) operations	2,292	(14,374)
Income tax paid	(889)	(2,943)
Nett cashflows from/(used in) operating activities	1,403	(17,317)
Cashflows from/(used in) investing activities:		
Advances to an associate	(7,103)	(12,897)
Purchase of property, plant and equipment	(6,493)	(5,151)
Proceeds from disposal of property, plant and equipment	11,956	478
Interests received	136	620
Nett cashflows used in investing activities	(1,504)	(16,950)
Cashflows from financing activities:		
Proceeds from issuance of shares	-	20,079
Drawdown of bills payable	1,415	283
Repayment of term loan and hire purchase payables	(347)	(820)
Interests on borrowings paid	(270)	(526)
Repayment of lease liabilities	(751)	(1,436)
Nett cashflows from financing activities	47	17,580
Nett decrease in cash and cash equivalents	(54)	(16,687)
Cash and cash equivalents at beginning of financial period	8,797	25,650
Effect of foreign exchange differences	947	(166)
Cash and cash equivalents at end of financial period	9,690	8,797
Cash and cash equivalents at end of financial period comprise the following:		
Cash and bank balances	10,123	9,217
Less: Fixed deposits pledged to bank	(433)	(420)
	9,690	8,797

The condensed consolidated statements of cashflows should be read in conjunction with the audited financial statements for the year ended 31 December 2024 and the accompanying notes attached to the interim financial statements.



NOTES TO THE INTERIM FINANCIAL REPORT FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2025

A. EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARD (“MFRS”) 134: INTERIM FINANCIAL REPORTING

1. Basis of Preparation of the Financial Statements and Adoption of New and Revised Malaysian Financial Reporting Standards (“MFRSs”)

The interim financial report is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standard (MFRS) 134: Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad and should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2024.

The accounting policies and methods of computation adopted for the interim financial statements were consistent with those adopted for the annual audited financial statements for the year ended 31 December 2024.

2. Auditor’s Report on Preceding Annual Financial Statements

The auditor’s report on the financial statements of the Group and the Company for the previous year ended 31 December 2024 was not subject to any qualification.

3. Seasonal or Cyclical Factors

The Group’s products are not materially impacted by any seasonal or cyclical factors.

4. Unusual Items due to their Nature, Size or Incidence

There were no unusual items affecting the Group’s assets, liabilities, equity, net income or cash flows in the financial statements for the period ended 30 September 2025.

5. Changes in Material Estimates

There were no changes in the nature and computation of estimates reported in prior financial year(s) that have a material effect in the financial statements for the period ended 30 September 2025.

6. Changes in Debt and Equity Securities

6.1 Share Buy-back

The Company did not carry out any Share Buy-back in the current quarter.

As of 30 September 2025, a total of 91,273,100 shares were held as Treasury Shares by the Company, and the net number of issued shares was 1,102,110,781 shares.

7. Dividends Paid

No dividends have been declared by the Company in respect of the current financial year.

**8. Segmental Information**

Segmental information is presented in accordance to business operating activities, which is the Group's primary reporting format.

	Gloves Operation RM'000	Medical Devices Operation RM'000	Property Investment RM'000	Current quarter ended 30 Sept 2025 RM'000	Cumulative year-to-date RM'000
Revenue	34,473	1,270	-	35,743	112,578
Segment Results	(4,096)	(281)	(978)	(5,355)	(16,063)
Investment Income	14	10	-	24	65
Finance Costs	(32)	(33)	-	(65)	(270)
Loss before Tax	(4,114)	(303)	(978)	(5,396)	(16,269)
Tax (Expense)/Credit	(413)	-	-	(413)	2,699
Loss after Tax	(4,527)	(303)	(978)	(5,809)	(13,569)

9. Valuation of Property, Plant and Equipment

The Group did not carry out any revaluations on its property, plant and equipment in the current quarter ended 30 September 2025.

The values of property, plant and equipment have been brought forward without amendment from the previous annual financial statements ended 31 December 2024.

10. Subsequent Events

There were no other material events subsequent to the end of the current quarter that have not been reflected in the financial period ended 30 September 2025.

11. Changes in the Composition of the Group

There were no changes to the composition of the Group including business combinations, acquisition or disposal of subsidiaries and long-term investments, restructuring and discontinuing operations since the last audited financial year ended 31 December 2024.

12. Changes in Contingent Liabilities or Contingent Assets

There were no changes in contingent liabilities or assets since the last audited annual balance sheet date of 31 December 2024.

13. Capital Commitments

There was no commitment for the purchase of property, plant and equipment not provided for in the financial statements for the period ended 30 September 2025.



B. ADDITIONAL INFORMATION PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD

1. Review of Performance

The Group recorded a revenue of RM35.7 million in the current quarter compared to RM30.4 million in the corresponding quarter ended 30 September 2024, an increase of RM5.3 million or 17.4%. Loss after tax in the current quarter amounted to RM5.8 million compared to RM4.1 million in the corresponding period of the previous year, an increase of RM1.7 million, which was driven by the higher production costs and lower capacity utilization of its plants in the current quarter compared to the corresponding period of the previous financial year.

For the first nine months of the year, the Group recorded a cumulative revenue of RM112.6 million, an increase of RM7.3 million or 6.9% from RM105.3 million in the corresponding period of previous year. However, the net loss had increased from RM5.9 million previously to RM13.6 million, due to the lower capacity utilization of its plants in the current year compared to the first nine months of 2024.

2. Material change in profits of the current quarter compared with preceding quarter

The Group recorded a loss after tax in the current quarter of RM5.8 million, compared to RM4.3 million in the preceding quarter, an increase of RM1.5 million or 34.9% mainly due to the higher operating costs and lower capacity utilization of its plants in the current quarter.

3. Current Year Prospects

The Management foresees the overall performance of the glove division to remain challenging in the short to medium term, amidst global trade uncertainties, foreign exchange risks and rising material prices, energy and labour costs. The Group's property investment division, which is expected to commence operations by the fourth quarter of this year would not have a material impact on the Group's earnings.

As for the medical device operation, the Group remains focused on the manufacture and sales of diagnostics test kits for the detection of various infectious diseases such as filariasis, malaria, typhoid, HIV and other drug-of-abuse test kits, which are distributed in Malaysia and overseas.

4. Profit Forecast or Profit Guarantee

No profit forecast or profit guarantee has been issued for the current quarter.

**5. Taxation (expense)/credit**

	Current quarter ended 30 Sept 2025 RM'000	Cumulative year- to-date RM'000
Current year – Malaysian income tax	(332)	(633)
Current year – Foreign income tax	(59)	(113)
Deferred tax asset/(liability)	(22)	3,445
Total income tax (expense)/credit	(413)	2,699

6. Sales of Unquoted Investments and/or Properties

There were no sales of unquoted investments and/or properties in the current quarter ended 30 September 2025.

7. Purchase/disposal of Quoted Securities

There were no purchase and/or disposal of quoted securities for the current quarter ended 30 September 2025.

8. (a) Status of Corporate Proposals

There were no corporate proposals not announced or outstanding as of 30 September 2025.

(b) Status of Utilisation of Proceeds

(i) On 03 August 2023, the Company announced an extension of time and variation to the utilization of proceeds raised from an earlier Private Placement exercise amounting to RM66.0 million. As of 30 September 2025, the proceeds have been fully utilized:

Purpose	Proposed Utilisation RM'000	Variation in Utilisation of Proceeds * RM'000
1. Acquisition of double-formers nitrile disposable glove production lines	66,024	-
2. Working capital	-	15,744
3. Fixed or short-term deposits – earmarked for future investments ^	-	50,280
4. Estimated expenses	558	-
TOTAL	66,582	66,024

* As announced on 03 August 2023

^ RM50.3 million had partially been utilised in the Group's property investment division, as well as in the purchase of property, plant and equipment, and working capital.

(ii) With regards to the proposed private placement of 100,191,000 shares which had been approved by Bursa Malaysia on 02 April 2024, a total of 100,191,000 Placement Shares had been issued pursuant to the Private Placement with total net proceeds of RM20.0 million raised and utilized as of 30 September 2025.



Purpose	Proposed Utilisation RM'000	Actual Utilization RM'000
Working capital	19,838	19,838
Estimated expenses	200	200
TOTAL	20,038	20,038

9. Group Borrowings and Debt Securities

	As of 30 September 2025		
	Secured RM'000	Unsecured RM'000	Total RM'000
Current	29	1,774	1,803
Non-current	-	51	51
	29	1,825	1,854

10. Financial Instruments Risks

As of 30 September 2025, the Group has the following foreign currency contracts outstanding: -

Currency	Contracted Amount '000	Ringgit Equivalent RM'000	Fair Value RM'000	Expiry Period
U.S. Dollar (USD)	104	435	434	October 2025
Euros (EUR)	4	21	21	October 2025

The above foreign currency contracts were entered into with local licensed banks to hedge the Group's receivables and payables in foreign currencies. The contracted rates will be used to translate the underlying foreign currencies into Ringgit Malaysia.

These foreign currency contracts are of a short-term nature. The accounting policy adopted with regards to off balance sheet financial instruments was consistent with those applied in the last audited financial statements as at 31 December 2024.

11. Changes in Material Litigation

There was no outstanding material litigation as of 30 September 2025.

12. Dividend Payable

No dividend is proposed for the current quarter ended 30 September 2025.



13. Earnings/(Loss) per Share

		Cumulative Year-to-Date ended 30 September 2025	Cumulative Year-to-Date ended 30 September 2024
Loss for the period attributable to equity holders of the Company	RM'000	(13,569)	(5.929)
Weighted average number of ordinary shares in issue	Shares	1,102,110,781	1,025,629,892
Loss per share	sen	(1.23)	(0.58)

14. Authorisation for Issue

The interim financial statements and explanatory notes were authorised for issue by the Board of Directors on 27 November 2025.